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questionnaires were administered pre- and post-interven-
tion to 126 heart-failure patients within a randomized
controlled trial at a university-affiliated teaching center
with a referral base of HF patients.
RESULTS: The internal consistency of the EMA was
0.79 (Cronbach’s alpha). The internal consistency of the
MKA was 0.61 and the responsiveness was 0.75.
CONCLUSIONS: The availability of instruments, such
as those we have developed, can assist heart-failure pro-
grams to evaluate the impact of their educational inter-
ventions on knowledge gained, which will hopefully
translate into better patient outcomes.
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OBJECTIVE: Joint National Committee on Detection,
Evaluation, and Treatment of High Blood Pressure V
(1993) and VI (1997) recommend diuretics and beta-
blockers as initial antihypertensive drugs. However, a
few studies have shown a trend of increasing use of an-
giotensin-converting enzyme inhibitors (ACEIs) and cal-
cium channel blockers (CCBs), and decreasing use of di-
uretics and beta-blockers. The purpose of the study was
to examine the impact of insurance types on patterns of
antihypertensive drug use.
METHODS: A logistic regression model was employed
to examine whether insurance type was associated with
patterns of antihypertensive drug use by using Medical
Expenditure Panel Survey (MEPS, 1996), after control-
ling for confounding variables. The estimated study pop-
ulation enrolled was 10,357,769 non-institutionalized
adult US patients with essential hypertension.
RESULTS: Patients with HMO insurance were less likely
to use diuretics or beta-blockers (OR  0.499, 95%CI:
0.323-0.770), compared with the patients with fee-for-
service (FFS) insurance. Black patients were less likely to
use diuretics or beta-blockers compared with white pa-
tients (OR  0.577, 95%CI: 0.346-0.961). Compared
with non-married patients, married patients were 92 per-
cent more likely to use diuretics or beta-blockers (OR 
1.92, 95%CI: 1.299-2.838). Finally, patients diagnosed
between 1988 and 1992, and after 1993 were less likely
to use diuretics or beta-blockers (OR  0.486, 95%CI:
0.289-0.817; OR  0.416, 95%CI: 0.251-0.691), com-
pared with patients who were diagnosed with hyperten-
sion before 1988.
CONCLUSION: Insurance types are associated with the
patterns of antihypertensive drug use. Patients with
HMO insurance used more ACEIs or CCBs than patients
with FFS insurance. Further research is required to dis-
cern the reasons for the impact of insurance types so that
policy makers can propose efficient intervention.
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Pharmacists, as easily accessible health-care professionals
and advisors to the general public, are distributors of in-
formation and dispensers of health-care products. The
“French Consensus Conference on Smoking Cessation” –
(October 1998), summed up the aims of pharmacists in
helping smoking cessation as follows: lead by example;
enforce smoking bans in pharmacies; underline the signif-
icant risks linked to cigarette smoking; encourage non
smoking; advise, aid and monitor the smoker who has
decided to stop smoking.
OBJECTIVE: To measure the progress of the French
Pharmacist’s Smoking Cessation Program.
METHODS: The STOP program, through a question-
naire distributed to approximately 2500 pharmacists,
aims at describing the progress pharmacists are making
with regard to their own tobacco dependence as well as
in the public health initiative entrusted to them.
RESULTS: Here we present the preliminary results of
this investigation, through the analysis of the first 300
questionnaires. The average age of our sample popula-
tion was 46 years, 55 % were male. 67% had attended a
smoking cessation course. Ninety percent of these at-
tended a course given by the pharmaceutical industry,
and 7% attended a course given by an anti-smoking or-
ganization. Ninety eight percent of the pharmacists that
replied offered information on aiding smoking cessation,
either through window displays(67%) or displays in the
pharmacy (70 %). After delivering a nicotine substitute,
80% of pharmacists do not arrange a follow-up appoint-
ment. This lack of follow-up is explained on the part of
the client by lack of motivation (48%) and clients not re-
turning to the same pharmacy (34%). For the pharmacist
the main reason is the absence of adequate follow-up
tools (54%).
CONCLUSION: Since the delisting of nicotine substi-
tutes, pharmacists have played a major role in their deliv-
ery and should therefore play a strategic role in the fight
against tobacco dependence.
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